{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:21:34Z","timestamp":1762608094994,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jval.2020.11.006","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T21:08:37Z","timestamp":1607893717000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health Economics of Vaccines: From Current Practice to Future Perspectives"],"prefix":"10.1016","volume":"24","author":[{"given":"Cornelis","family":"Boersma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2020.11.006_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","article-title":"Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community","volume":"34","author":"Ultsch","year":"2016","journal-title":"Phamaceconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2020.11.002","article-title":"Cost-effectiveness of quadrivalent versus trivalent influenza vaccination in the Dutch National Influenza Prevention Program","volume":"24","author":"Zeevat","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jval.2020.10.013","article-title":"Consultations for influenza-like illness in primary care in The Netherlands: a regression approach","volume":"24","author":"Dolk","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jval.2020.10.011","article-title":"Cost-effectiveness of pediatric influenza vaccination in The Netherlands","volume":"24","author":"de Boer","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jval.2020.05.022","article-title":"Cost-effectiveness of routine childhood vaccination against seasonal influenza in Germany","volume":"24","author":"Scholz","year":"2021","journal-title":"Value Health"},{"issue":"13","key":"10.1016\/j.jval.2020.11.006_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12916-015-0452-y","article-title":"Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study","volume":"13","author":"Baguelin","year":"2015","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.jval.2020.11.006_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ebiom.2015.09.014","article-title":"The \u201cdynamic\u201d marriage between varicella and zoster","volume":"2","author":"de Boer","year":"2015","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.jval.2020.11.006_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14760584.7.6.753","article-title":"Cost-effectiveness of varicella vaccination programs: an update of the literature","volume":"7","author":"Rozenbaum","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jval.2020.07.011","article-title":"Integrating alternative social value judgments into cost-effectiveness analysis of vaccines: an application to varicella-zoster virus\u00a0vaccination","volume":"24","author":"Luyten","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jval.2020.10.004","article-title":"What we know now: an economic evaluation of chickenpox vaccination and dose timing using an agent-based model","volume":"24","author":"Rafferty","year":"2021","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2020.11.006_bib13","doi-asserted-by":"crossref","first-page":"E406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jval.2020.07.012","article-title":"Informing global cost-effectiveness thresholds using country investment decisions: human papillomavirus vaccine introductions in 2006-2018","volume":"24","author":"Jit","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jval.2020.08.2097","article-title":"What we don not know about the costs of immunization programs in low- and middle-income countries","volume":"24","author":"Portnoy","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jval.2020.07.010","article-title":"Costs of immunization programs for 10 vaccines in 94 low-and middle-income countries from 2011 to 2030","volume":"24","author":"Sim","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jval.2020.07.009","article-title":"Economic benefits of immunization for 10 pathogens in 94 low- and middle-income countries from 2011 to 2030 using cost-of-illness and value-of-statistical-life approaches","volume":"24","author":"Watts","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jval.2020.06.018","article-title":"Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can\u00a0we capture the value of risk reduction?","volume":"24","author":"Mauskopf","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","article-title":"Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease","volume":"24","author":"Beck","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.11.006_bib20","doi-asserted-by":"crossref","DOI":"10.3402\/jmahp.v4.33039","article-title":"Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement","author":"Schlander","year":"2016","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"2","key":"10.1016\/j.jval.2020.11.006_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2020.11.006_bib22","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2214-109X(13)70170-0","article-title":"Reassessing the value of vaccines","volume":"2","author":"B\u00e4rnighausen","year":"2014","journal-title":"Lancet Global Health"},{"issue":"6","key":"10.1016\/j.jval.2020.11.006_bib23","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S1473-3099(17)30478-4","article-title":"Use of mathematical modelling to access the impact of vaccines on antibiotic resistance","volume":"18","author":"Atkins","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jval.2020.11.006_bib24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40273-016-0414-z","article-title":"Extended cost-effectiveness analysis for health\u00a0policy assessment: a tutorial","volume":"34","author":"Verguet","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.11.006_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jval.2020.09.005","article-title":"Economic evaluation of vaccines: Belgian reflections on the need for a broader perspective","volume":"24","author":"Annemans","year":"2021","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:21:42Z","timestamp":1761096102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520345198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1098301520345198"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Economics of Vaccines: From Current Practice to Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}